<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00107237</url>
  </required_header>
  <id_info>
    <org_study_id>CAEE788A2106</org_study_id>
    <secondary_id>UCLA-0409004-01</secondary_id>
    <secondary_id>CDR0000422335</secondary_id>
    <nct_id>NCT00107237</nct_id>
  </id_info>
  <brief_title>AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme</brief_title>
  <official_title>A Phase IB/II Multicenter, Two-Arm, Dose-Escalation Study of Oral AEE788 Administered in Combination With Oral RAD001 on a Continuous Once Daily Dosing Schedule in Adult Patients With First or Second Recurrent or Relapsing Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      RATIONALE: AEE788 and everolimus may stop the growth of tumor cells by blocking some of the&#xD;
      enzymes needed for cell growth and by blocking blood flow to the tumor. Giving AEE788&#xD;
      together with everolimus may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of AEE788 when&#xD;
      given together with everolimus and to see how well they work in treating patients with&#xD;
      recurrent or relapsed glioblastoma multiforme.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose and dose-limiting toxicity of AEE788 when&#xD;
           administered in combination with 1 of 2 different doses of everolimus in patients with&#xD;
           recurrent or relapsed glioblastoma multiforme.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the safety and tolerability of this regimen, including acute and chronic toxic&#xD;
           effects, in these patients.&#xD;
&#xD;
        -  Determine the single-dose and repeated-dose pharmacokinetic profile of this regimen in&#xD;
           these patients.&#xD;
&#xD;
        -  Determine, preliminarily, the efficacy of this regimen, in terms of response rate,&#xD;
           progression-free survival, and overall survival, in these patients. (Phase II)&#xD;
&#xD;
        -  Determine the antiangiogenic effects of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter, dose-escalation study of AEE788.&#xD;
&#xD;
        -  Phase I: Patients are assigned to 1 of 2 treatment groups.&#xD;
&#xD;
             -  Group 1: Patients receive oral AEE788 once daily and oral everolimus once daily on&#xD;
                days 1-28.&#xD;
&#xD;
             -  Group 2: Beginning at the first occurrence of dose-limiting toxicity in group 1,&#xD;
                patients receive AEE788 as in group 1 and a higher-dose of oral everolimus once&#xD;
                daily on days 1-28.&#xD;
&#xD;
      In both groups, courses repeat every 28 days in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients per group receive escalating doses of AEE788 until the maximum&#xD;
      tolerated dose is determined.&#xD;
&#xD;
        -  Phase II: Patients are assigned to 1 of 2 treatment groups according to eligibility for&#xD;
           surgery.&#xD;
&#xD;
             -  Group 1 (eligible for tumor biopsy, surgical resection, or tumor debulking):&#xD;
                Patients receive oral AEE788 once daily at the MTD and oral everolimus once daily&#xD;
                for 5-9 days. Patients then undergo surgery. Beginning 15-21 days after surgery,&#xD;
                patients receive oral AEE788 and oral everolimus once daily on days 1-28.&#xD;
&#xD;
             -  Group 2 (ineligible for surgery): Patients receive oral AEE788 once daily at the&#xD;
                MTD and oral everolimus once daily on days 1-28.&#xD;
&#xD;
      In both groups, courses repeat every 28 days in the absence of disease progression or&#xD;
      unacceptable toxicity. In both phases, if treatment with AEE788 or everolimus is stopped due&#xD;
      to toxicity, patients may continue to receive AEE788 or everolimus alone once daily.&#xD;
&#xD;
      After the completion of study treatment, patients are followed every 3 months for as long as&#xD;
      the investigator deems necessary.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose and dose-limiting toxicity of AEE788</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single-dose and repeated-dose pharmacokinetic profile</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy (response rate, progression-free survival, and overall survival)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiangiogenic effects</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <arm_group>
    <arm_group_label>AEE788 200 mg + RAD001 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AEE788 200 mg qd, RAD001 5 mg qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AEE788 150 mg + RAD001 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AEE788 150 mg qd, RAD001 5 mg qod</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AEE788</intervention_name>
    <description>AEE788 was available in the form of a hard gelatin capsule of 50 mg or 100 mg strengths and packaged in bottles.</description>
    <arm_group_label>AEE788 150 mg + RAD001 5mg</arm_group_label>
    <arm_group_label>AEE788 200 mg + RAD001 5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>everolimus</intervention_name>
    <description>Everolimus was formulated as tablets of 2.5 mg and 5 mg strength and supplied in blister packs.</description>
    <arm_group_label>AEE788 150 mg + RAD001 5mg</arm_group_label>
    <arm_group_label>AEE788 200 mg + RAD001 5 mg</arm_group_label>
    <other_name>RAD001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed glioblastoma multiforme, meeting 1 of the following criteria:&#xD;
&#xD;
               -  Phase I&#xD;
&#xD;
                    -  In first or second recurrence or relapse&#xD;
&#xD;
                    -  At least 1 measurable or evaluable enhancing lesion by gadolinium MRI&#xD;
                       (Gd-MRI) of the brain within the past 3 weeks&#xD;
&#xD;
               -  Phase II, group 1&#xD;
&#xD;
                    -  In first or second recurrence or relapse by Gd-MRI of the brain within the&#xD;
                       past 3 weeks&#xD;
&#xD;
                    -  Requires tumor biopsy OR surgical resection for tumor debulking or for&#xD;
                       confirmation of recurrence&#xD;
&#xD;
               -  Phase II, group 2&#xD;
&#xD;
                    -  In first recurrence or relapse&#xD;
&#xD;
                    -  At least 1 bidimensionally measurable enhancing lesion (≥ 1.5 cm^2 using&#xD;
                       product of the largest perpendicular diameters) by Gd-MRI of the brain&#xD;
                       within the past 3 weeks&#xD;
&#xD;
          -  Multifocal disease allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times ULN&#xD;
&#xD;
          -  No acute or chronic liver disease&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Total calcium (corrected) normal*&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  No proteinuria by dipstick OR&#xD;
&#xD;
          -  Total urinary protein ≤ 500 mg AND creatinine clearance ≥ 50 mL/min by 24-hour urine&#xD;
             collection&#xD;
&#xD;
          -  No acute or chronic renal disease NOTE: *Supplements allowed&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF ≥ 45% by MUGA or echocardiogram&#xD;
&#xD;
          -  No complete left bundle branch block&#xD;
&#xD;
          -  No requirement for a cardiac pacemaker&#xD;
&#xD;
          -  No congenital long QT syndrome&#xD;
&#xD;
          -  No ventricular or atrial tachyarrhythmias&#xD;
&#xD;
          -  No clinically significant resting bradycardia, defined as &lt; 50 beats per minute&#xD;
&#xD;
          -  QTc ≤ 480 msec by ECG&#xD;
&#xD;
          -  No right bundle branch block and left anterior hemiblock (bifascicular block)&#xD;
&#xD;
          -  No uncontrolled hypertension OR history of labile hypertension&#xD;
&#xD;
          -  No unstable angina pectoris OR angina pectoris occurrence within the past 3 months&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No acute myocardial infarction within the past 3 months&#xD;
&#xD;
          -  No history of poor compliance with an antihypertensive regimen&#xD;
&#xD;
          -  No other impaired cardiac function or clinically significant cardiac disease&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No unresolved diarrhea ≥ grade 2&#xD;
&#xD;
          -  No impairment of gastrointestinal (GI) function or GI disease that would significantly&#xD;
             alter absorption of study drugs, including any of the following:&#xD;
&#xD;
               -  Ulcerative disease&#xD;
&#xD;
               -  Uncontrolled nausea&#xD;
&#xD;
               -  Vomiting&#xD;
&#xD;
               -  Malabsorption syndrome&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception&#xD;
&#xD;
          -  Potassium normal*&#xD;
&#xD;
          -  Magnesium normal*&#xD;
&#xD;
          -  Phosphorus normal*&#xD;
&#xD;
          -  Cholesterol ≤ 300 mg/dL (treatment allowed)&#xD;
&#xD;
          -  Triglycerides ≤ 2.5 times ULN (treatment allowed)&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  No peripheral neuropathy ≥ grade 2&#xD;
&#xD;
          -  No uncontrolled diabetes&#xD;
&#xD;
          -  No active or uncontrolled infection&#xD;
&#xD;
          -  No other severe and/or uncontrolled medical condition that would preclude study&#xD;
             participation or compliance&#xD;
&#xD;
          -  No contraindication to MRI, including any of the following:&#xD;
&#xD;
               -  Cardiac pacemaker&#xD;
&#xD;
               -  Ferromagnetic metal implants other than those approved as safe for use with&#xD;
                  magnetic resonance scanners (e.g., some types of aneurysm clips or shrapnel)&#xD;
&#xD;
               -  Claustrophobia&#xD;
&#xD;
               -  Obesity exceeding magnetic resonance equipment limits&#xD;
&#xD;
          -  No other clinically significant primary malignancy requiring active intervention NOTE:&#xD;
             *Supplements allowed&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 2 weeks since prior hematopoietic colony-stimulating factors (e.g.,&#xD;
             filgrastim [G-CSF] or sargramostim [GM-CSF]) except epoetin alfa&#xD;
&#xD;
          -  More than 2 weeks since prior immunotherapy and recovered&#xD;
&#xD;
          -  No concurrent biologic therapy&#xD;
&#xD;
          -  No concurrent prophylactic hematopoietic growth factors (e.g., G-CSF or GM-CSF) unless&#xD;
             approved by the study sponsor&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
          -  Prior polifeprosan 20 with carmustine implant (Gliadel® wafer) allowed&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Must be on stable or deceasing doses of steroids for at least 7 days before baseline&#xD;
             Gd-MRI of the brain and before starting study drug&#xD;
&#xD;
          -  No concurrent tamoxifen&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 1 week since prior tumor biopsy&#xD;
&#xD;
          -  More than 2 weeks since prior surgical resection&#xD;
&#xD;
          -  More than 2 weeks since prior major non-CNS surgery and recovered&#xD;
&#xD;
          -  No prior small bowel resection&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 2 weeks since prior and no concurrent enzyme-inducing anticonvulsant drugs&#xD;
&#xD;
          -  More than 4 weeks since prior investigational drugs and recovered&#xD;
&#xD;
          -  No prior epidermal growth factor receptor- or ErbB-2-directed therapy (phase II only)&#xD;
&#xD;
          -  No prior vascular endothelial growth factor (VEGF) or VEGF receptor-directed therapy&#xD;
             (phase II only)&#xD;
&#xD;
          -  No prior mTOR-directed therapy (phase II only)&#xD;
&#xD;
          -  No concurrent therapeutic warfarin&#xD;
&#xD;
          -  No concurrent treatment with any medication that may prolong QT interval, including&#xD;
             any of the following:&#xD;
&#xD;
               -  Quinidine&#xD;
&#xD;
               -  Procainamide&#xD;
&#xD;
               -  Disopyramide&#xD;
&#xD;
               -  Amiodarone&#xD;
&#xD;
               -  Sotalol&#xD;
&#xD;
               -  Bretylium&#xD;
&#xD;
               -  Ibutilide&#xD;
&#xD;
               -  Thioridazine&#xD;
&#xD;
               -  Mesoridazine&#xD;
&#xD;
               -  Chlorpromazine&#xD;
&#xD;
               -  Amitriptyline&#xD;
&#xD;
               -  Imipramine&#xD;
&#xD;
               -  Desipramine&#xD;
&#xD;
               -  Doxepin&#xD;
&#xD;
               -  Erythromycin&#xD;
&#xD;
               -  Clarithromycin&#xD;
&#xD;
               -  Ketoconazole&#xD;
&#xD;
               -  Halofantrine&#xD;
&#xD;
               -  Quinine&#xD;
&#xD;
               -  Chloroquine&#xD;
&#xD;
               -  Mefloquine&#xD;
&#xD;
               -  Moxifloxacin&#xD;
&#xD;
               -  Gatifloxacin&#xD;
&#xD;
               -  Pimozide&#xD;
&#xD;
               -  Risperidone&#xD;
&#xD;
               -  Ziprasidone&#xD;
&#xD;
               -  Venlafaxine&#xD;
&#xD;
               -  Maprotiline&#xD;
&#xD;
               -  Lithium&#xD;
&#xD;
               -  Pentamidine&#xD;
&#xD;
               -  Droperidol&#xD;
&#xD;
               -  Dolasetron&#xD;
&#xD;
          -  No concurrent digoxin or verapamil&#xD;
&#xD;
          -  No concurrent tacrolimus&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Univaersity Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center/University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>April 5, 2005</study_first_submitted>
  <study_first_submitted_qc>April 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2005</study_first_posted>
  <last_update_submitted>June 11, 2013</last_update_submitted>
  <last_update_submitted_qc>June 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult glioblastoma</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

